https://www.prnewswire.com/news/isis-pharmaceuticals%2C-inc.%3B-chdi-foundation%2C-inc./
Isis Pharmaceuticals, Inc.; CHDI Foundation, Inc. News and Press Releases | PR Newswire
news and press releasesisis pharmaceuticalschdi foundationinc
https://www.epo.org/de/boards-of-appeal/decisions/t091434eu1
T 1434/09 (Oligonucleotides/ISIS PHARMACEUTICALS) vom 14.05.2013
isis pharmaceuticals14 05143409oligonucleotides
https://www.news-medical.net/news/20140521/Isis-Pharmaceuticals-starts-Phase-1-clinical-study-of-ISIS-PKKRx-to-treat-patients-with-HAE.aspx
Isis Pharmaceuticals starts Phase 1 clinical study of ISIS-PKKRx to treat patients with HAE
Jun 20, 2019 - Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it initiated a Phase 1 clinical study of ISIS-PKKRx. ISIS-PKKRx is an antisense drug in...
https://www.news-medical.net/news/20091022/Positive-results-from-Isis-Pharmaceuticals-ISIS-113715-Phase-2-study-in-type-2-diabetes-patients.aspx
Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients
Jun 20, 2019 - Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with...
phase 2 study
https://www.fool.com/investing/general/2014/02/27/3-things-to-watch-when-isis-pharmaceuticals-report.aspx
3 Things to Watch When Isis Pharmaceuticals Reports 2013 Earnings | The Motley Fool
Feb 27, 2014 - This RNA therapeutics powerhouse should provide some insightful updates as it enters a critical point in its growth.
things to watch
https://www.lawinsider.com/contracts/cbbxfgLH9xS
CALL OPTION AGREEMENT BY AND AMONG ISIS PHARMACEUTICALS, INC., IBIS BI... | Law Insider
CALL OPTION AGREEMENT BY AND AMONG ISIS PHARMACEUTICALS, INC., IBIS BIOSCIENCES, INC. AND ABBOTT MOLECULAR INC. January 30, 2008 filed by Isis Pharmaceuticals...
https://www.biospace.com/isis-pharmaceuticals-inc-earns-10-million-milestone-payment-from-biogen-idec-for-advancing-new-drug-into-development-to-treat-a-neurodegenerative-d
Isis Pharmaceuticals, Inc. Earns $10 Million Milestone Payment From Biogen Idec For Advancing New...